Seminars in Cancer Biology

Article	Citations
Ferroptosis is a type of autophagy-dependent cell death	625
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy	323
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges	237
The role of SOX family members in solid tumours and metastasis	229
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer	224
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy	220
SOX2 in development and cancer biology	202
Radiomics in breast cancer classification and prediction	198
Targeting p53 for the treatment of cancer	185
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond	183
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics	180
RAF-MEK-ERK pathway in cancer evolution and treatment	166
Curcumin and colorectal cancer: An update and current perspective on this natural medicine	154
lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions	148
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art	147
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives	147
Pathology of triple negative breast cancer	145
Machine and deep learning approaches for cancer drug repurposing	140
An update on vitamin D signaling and cancer	138
Regulation of autophagy by canonical and non-canonical ER stress responses	137
Dietary fat, bile acid metabolism and colorectal cancer	131
SOX4: The unappreciated oncogene	131
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC	128
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects	127
An updated overview on metal nanoparticles toxicity	120

The complexity of p53-mediated metabolic regulation in tumor suppression	120
Regulation and function of SOX9 during cartilage development and regeneration	115
The impact of VEGF on cancer metastasis and systemic disease	115
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer	114
Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges	112
Epigenetics in hepatocellular carcinoma	108
Precision medicine in non-small cell lung cancer: Current applications and future directions	107
PROTACs: A novel strategy for cancer therapy	107
DNMT1: A key drug target in triple-negative breast cancer	105
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics	104
The oral microbiota and its role in carcinogenesis	103
EGFR signaling pathway as therapeutic target in human cancers	102
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer	101
Artificial intelligence aids in development of nanomedicines for cancer management	101
Tumor glycolysis, an essential sweet tooth of tumor cells	99
The Skp2 Pathway: A Critical Target for Cancer Therapy	99
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches	98
TGF-β in developmental and fibrogenic EMTs	97
Neutrophil extracellular traps in cancer	97
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics	96
RNA methylations in human cancers	95
Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement	92
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers	91
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer	91
Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds	89
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies	88
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities	87
Drug repurposing for breast cancer therapy: Old weapon for new battle	86
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics	86
Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review	85
Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis	84
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy	81
Colorectal cancer occurrence and treatment based on changes in intestinal flora	80
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications	79
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives	78
Hedgehog signaling mechanism and role in cancer	78
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology	77
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine	77
Recent insight into the role of FBXW7 as a tumor suppressor	77
Dissenting degradation: Deubiquitinases in cell cycle and cancer	76
NEDD4 E3 ligase: Functions and mechanism in human cancer	75
Mechanisms of cancer metastasis	75
Circular RNAs in cancer: Limitations in functional studies and diagnostic potential	75
AMPK signaling and its targeting in cancer progression and treatment	74
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature	74
SOX4: Epigenetic regulation and role in tumorigenesis	74
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications	73
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress	73
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments	73
Role of iron in cancer	73

Predictive biomarkers for response to immune checkpoint inhibition	72
The potential of liquid biopsy in the management of cancer patients	72
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective	72
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer	72
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer	71
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy	70
Molecular targets of tyrosine kinase inhibitors in thyroid cancer	70
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis	70
PD-L1 status in breast cancer: Current view and perspectives	69
Chemokines in colon cancer progression	69
Functionalized mesoporous silica nanoparticles in anticancer therapeutics	69
At a glance: A history of autophagy and cancer	69
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets	68
Cellular heterogeneity and plasticity in liver cancer	68
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer	68
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy	67
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance	67
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors	67
Circular RNAs as biomarkers and therapeutic targets in cancer	67
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis	67
Extracellular vesicles in cancer nanomedicine	66
Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives	65
Vimentin and cytokeratin: Good alone, bad together	65
Anticancer activity of lactic acid bacteria	64
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis	64
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives	64
miRNA dysregulation is an emerging modulator of genomic instability	64
The intricacies of NRF2 regulation in cancer	64
The functions and regulation of Smurfs in cancers	63
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy	62
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine	61
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer	60
Engineered nanoparticles for imaging and drug delivery in colorectal cancer	59
RBR E3 ubiquitin ligases in tumorigenesis	59
Repurposing of drugs as STAT3 inhibitors for cancer therapy	59
Excess body weight: Novel insights into its roles in obesity comorbidities	57
Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy	57
Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches	56
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment	56
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology	56
Nano-immunotherapy: Overcoming tumour immune evasion	54
RNA-binding proteins and cancer metastasis	54
Systems biology based drug repositioning for development of cancer therapy	53
Dysregulated FOXM1 signaling in the regulation of cancer stem cells	53
Small cell lung cancer transformation: From pathogenesis to treatment	52
Effects of statins on brain tumors: a review	52
Nanoparticle mediated cancer immunotherapy	52
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better	52
Implications of nanotechnology for the treatment of cancer: Recent advances	52
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment	52
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy	52
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic	52
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-19	51
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer	51
Interference between copper transport systems and platinum drugs	51
Regulatory roles for SOX11 in development, stem cells and cancer	51
Turning liabilities into opportunities: Off-target based drug repurposing in cancer	51
Glyco-nanoparticles: New drug delivery systems in cancer therapy	51
Repurposing quinacrine for treatment-refractory cancer	51
Transcription factors in SOX family: Potent regulators for cancer initiation and development in the human body	50
Vaginal microbiome and cervical cancer	50
Targeting NRF2 to treat cancer	50
Uveal melanoma pathobiology: Metastasis to the liver	48
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities	48
Biological functions of therapy-induced senescence in cancer	48
Probiotics in microbiome ecological balance providing a therapeutic window against cancer	48
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance	47
Microbiota and gastric cancer	47
How far have we explored fungi to fight cancer?	47
The evolutionary legacy of immune checkpoint inhibitors	47
Polyploidy formation in cancer cells: How a Trojan horse is born	46
Cancer stem cells in TNBC	46
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling	46
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy	46
Cancer epigenetics: Past, present and future	46
Dendrimers as nanoscale vectors: Unlocking the bars of cancer therapy	46
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy	46
Repurposing drugs in oncology: From candidate selection to clinical adoption	45
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment	45
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation	45

Emerging roles of long non-coding RNAs in breast cancer biology and management	45
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases	45
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib	45
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies	45
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?	45
Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme	45
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment	44
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent	44
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging	44
Gold nanoparticles and cancer: Detection, diagnosis and therapy	44
Understanding and targeting prostate cancer cell heterogeneity and plasticity	44
Cullin-RING Ligase 5: Functional characterization and its role in human cancers	43
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review	43
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy	43
STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges	42
ITCH as a potential therapeutic target in human cancers	42
MicroRNA and ER stress in cancer	42
New Advances in Molecular Breast Cancer Pathology	42
Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers	41
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era	41
The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance	41
Emerging applications of bacteria as antitumor agents	41
Microbes-mediated synthesis strategies of metal nanoparticles and their potential role in cancer therapeutics	41
Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data	40
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications	40
Epigenetic modifications of autophagy in cancer and cancer therapeutics	40
The two sides of Hippo pathway in cancer	40
Genome chaos: Creating new genomic information essential for cancer macroevolution	40
Transcriptomics and solid tumors: The next frontier in precision cancer medicine	40
Autophagy in cancer: Recent advances and future directions	40
Deep computational pathology in breast cancer	40
Radiation therapy-induced remodeling of the tumor immune microenvironment	39
Tumor hypoxia: From basic knowledge to therapeutic implications	39
RNA-binding proteins in regulating mRNA stability and translation: roles and mechanisms in cancer	39
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications	39
Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma	39
Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator	39
Multiple endocrine neoplasia type 2: A review	39
Clinical utility of whole-genome sequencing in precision oncology	39
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer	39
Novel molecular regulators of breast cancer stem cell plasticity and heterogeneity	39
Drug rechanneling: A novel paradigm for cancer treatment	38
Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges	38
Targeting the tumour microenvironment in platinum-resistant ovarian cancer	38
Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model	38
Cyclin D degradation by E3 ligases in cancer progression and treatment	38
Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention	38
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors	38
Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer	38
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update	38
SOX17 in cellular reprogramming and cancer	37
Arsenic co-carcinogenesis: Inhibition of DNA repair and interaction with zinc finger proteins	37
Microbiota and prostate cancer	37
Small cell lung cancer: Novel treatments beyond immunotherapy	37
Surgery-mediated tumor-promoting effects on the immune microenvironment	37
Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplas	37
New approaches for targeting platinum-resistant ovarian cancer	37
Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer	37
Multifaceted role of chemokines in solid tumors: From biology to therapy	37
Carcinogenic microbiota and its role in colorectal cancer development	37
Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: Micromanaging by not so small non-coding RNAs	37
Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer	37
Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways	37
Polyploid giant cancer cells: An emerging new field of cancer biology	37
HDL and cancer - causality still needs to be confirmed? Update 2020	36
Paradoxes of cancer: Survival at the brink	36
Significance of human microbiome in breast cancer: Tale of an invisible and an invincible	36
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation	35
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems	35
The clinical value of detecting microcalcifications on a mammogram	35
Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics	35
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment	35
Necroptosis pathways in tumorigenesis	35
Drug repurposing for cancer therapy, easier said than done	35
Targeting the acetylation signaling pathway in cancer therapy	35
Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy	35
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells	35
Pomegranate bioactive constituents target multiple oncogenic and oncosuppressive signaling for cancer prevention and intervention	35
The unique immune microenvironment of liver metastases: Challenges and opportunities	35
Targeting monocarboxylate transporters (MCTs) in cancer: How close are we to the clinics?	35
Bacteria as a treasure house of secondary metabolites with anticancer potential	34
Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives	34
The role of tumor microenvironment and exosomes in dormancy and relapse	34
Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma	34
Targeting matrix metalloproteinases by E3 ubiquitin ligases as a way to regulate the tumor microenvironment for cancer therapy	34
Arsenic-induced epigenetic changes in cancer development	34
Targeting epigenetic regulatory machinery to overcome cancer therapy resistance	34
Targeting tumor cell senescence and polyploidy as potential therapeutic strategies	34
Dietary isothiocyanates inhibit cancer progression by modulation of epigenome	33
Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer	33
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies	33
Current state and future perspective of drug repurposing in malignant glioma	33
Curcumin: A therapeutic strategy for colorectal cancer?	32
Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma	32
Chemotherapy as a regulator of extracellular matrix-cell communication: Implications in therapy resistance	32